PositiveID Corporation Completes Milestone in Development of Its Firefly Dx Prototype

Delray Beach, FL - PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a developer of biological detection and diagnostics solutions, announced recently that it has completed the design of the second-phase (bench-top) prototype, the first major milestone in the development of the Firefly Dx second-phase prototype. With the completion of this design, the Company has begun to build the second-phase prototype of Firefly Dx, a real- time, handheld, polymerase chain reaction (PCR) pathogen detection system, which it expects to complete during the first half of 2015.

The Company believes that this completed second-phase prototype will have the capability to test biological samples in less than half the time of the first-phase prototypes and run data for potential partners and customers, a key element in the development of the final prototype to be used in field testing in late 2015.

In the third quarter of 2014 the Company announced that it accelerated the Firefly Dx development with the second-phase prototype, and engaged Infinite Vision, a specialized engineering firm with medical device and biotechnology expertise. The Company is now assembling the hardware components required to complete the second phase device and build the prototype that demonstrates the functionality, speed, sensitivity, and specificity of the Firefly Dx system.

"The market opportunities and critical need for a rapid diagnostic device like Firefly Dx, which can be used in the field without bulky lab equipment, are very significant," said William J. Caragol, PositiveID's Chairman and Chief Executive Officer. "Whether utilized by the healthcare or defense communities for detecting various strains of influenza, biological weapons of mass destruction, Ebola, or other pathogens, Firefly Dx is designed to be a simple-to-use device that provides lab-quality, real-time PCR results anywhere, anytime, within minutes to save lives."

About PositiveID Corporation PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats and analyze biological samples. For more information on PositiveID, please visit http://www.PositiveIDCorp.com.